Latest & greatest articles for liraglutide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on liraglutide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on liraglutide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for liraglutide

81. Insulin degludec/liraglutide (Addendum to Commission A15-15)

Insulin degludec/liraglutide (Addendum to Commission A15-15) 1 Translation of addendum A15-36 Insulin degludec/Liraglutid (Addendum zum Auftrag A15-15) (Version 1.0; Status: 24 September 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 24 September 2015 1.0 Commission: A15-36 Version: Status: IQWiG Reports – Commission No. A15-36 Insulin degludec (...) /liraglutide (Addendum to Commission A15-15) 1 Addendum A15-36 Version 1.0 Insulin degludec/liraglutide (Addendum to Commission A15-15) 24 September 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin degludec/liraglutide (Addendum to Commission A15-15) Commissioning agency: Federal Joint Committee Commission awarded on: 8 September 2015 Internal Commission No.: A15-36 Address of publisher

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

82. Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment)

Insulin degludec/liraglutide (new therapeutic indication): benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Insulin degludec/Liraglutid (neues Anwendungsgebiet) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11. November 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A15-30 Insulin degludec/liraglutide (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A15-30 Version 1.0 Insulin degludec/liraglutide (new TI) – Benefit assessment acc. to §35a SGB V 11 Nov 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Insulin degludec/liraglutide (new

2015 Institute for Quality and Efficiency in Healthcare (IQWiG)

83. Saxenda - liraglutide

Saxenda - liraglutide 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 11 February 2015 EMA/143005/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Saxenda International non-proprietary name: liraglutide (...) diet LDL low-density lipoprotein Lira 3.0 mg liraglutide 3.0 mg LOCF last observation carried forward Assessment report EMA/143005/2015 Page 5/91 LoQ list of questions LRQA Lloyd's Register Quality Assurance LS least square Lys lysine MAA marketing authorization application N/A not applicable NA not applicable NGSP National Glycohaemoglobin Standardization Program OAD oral antidiabetic drug OD optical density OGTT oral glucose tolerance test OR odds ratio OSA obstructive sleep apnoea PAI-1

2015 European Medicines Agency - EPARs

84. Liraglutide and the Preservation of Pancreatic beta-Cell Function in Early Type 2 Diabetes: The LIBRA Trial Full Text available with Trip Pro

Liraglutide and the Preservation of Pancreatic beta-Cell Function in Early Type 2 Diabetes: The LIBRA Trial Clinical studies evaluating the effects of medications on β-cell function in type 2 diabetes (T2DM) are compromised by an inability to determine the actual baseline degree of β-cell dysfunction independent of the reversible dysfunction induced by hyperglycemia (glucotoxicity). Short-term intensive insulin therapy (IIT) is a strategy for eliminating glucotoxicity before randomization (...) . This study determined whether liraglutide can preserve β-cell function over 48 weeks in early T2DM following initial elimination of glucotoxicity with IIT.In this double-blind, randomized, placebo-controlled trial, 51 patients with T2DM of 2.6 ± 1.9 years' duration and an A1C of 6.8 ± 0.8% (51 ± 8.7 mmol/mol) completed 4 weeks of IIT before randomization to daily subcutaneous liraglutide or placebo injection, with serial assessment of β-cell function by Insulin Secretion-Sensitivity Index-2 (ISSI-2

2014 EvidenceUpdates Controlled trial quality: predicted high

85. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs Full Text available with Trip Pro

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme.Initiators of liraglutide, exenatide, metformin, pioglitazone or groups containing initiators of dipeptidyl peptidase-4 inhibitors or sulfonylureas were identified in a US commercial health insurance (...) claims database (1 February 2010 to 31 March 2013) and followed for a median of 15 months. We estimated incidence rates (IR/100 000 person-years), rate ratio (RR) and 95% confidence intervals (CI) of new insurance claims with diagnoses of primary inpatient acute pancreatitis or pancreatic cancer from Poisson regression models.The IR for acute pancreatitis for liraglutide was 187.5 compared with 154.4 for all non-glucagon-like peptide-1 (GLP-1)-based therapies (adjusted RR 1.10; CI 0.81-1.49). The IR

2014 EvidenceUpdates

86. Xultophy - insulin degludec / liraglutide

Xultophy - insulin degludec / liraglutide 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. 24 July 2014 EMA/CHMP/369341/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Xultophy International non (...) -proprietary name: insulin degludec / liraglutide Procedure No. EMEA/H/C/002647/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 2 Table of contents 1. Background information on the procedure 4 1.1. Submission of the dossier 4 1.2. Manufacturers 5 1.3. Steps taken for the assessment of the product 5 2. Scientific discussion 6 2.1. Introduction 6 2.2. Quality aspects 8 2.3. Non-clinical aspects 14 2.4. Clinical aspects 18 2.5. Clinical

2014 European Medicines Agency - EPARs

87. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. (Abstract)

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. In a head-to-head trial, we compared the safety and efficacy of once-weekly dulaglutide with that of once-daily liraglutide in metformin-treated patients (...) with uncontrolled type 2 diabetes.We did a phase 3, randomised, open-label, parallel-group study at 62 sites in nine countries between June 20, 2012, and Nov 25, 2013. Patients with inadequately controlled type 2 diabetes receiving metformin (≥1500 mg/day), aged 18 years or older, with glycated haemoglobin (HbA1c) 7·0% or greater (≥53 mmol/mol) and 10·0% or lower (≤86 mmol/mol), and body-mass index 45 kg/m(2) or lower were randomly assigned to receive once-weekly dulaglutide (1·5 mg) or once-daily liraglutide

2014 Lancet Controlled trial quality: predicted high

88. Liraglutide for obesity or overweight in patients with associated co-morbidities

Liraglutide for obesity or overweight in patients with associated co-morbidities Liraglutide for obesity or overweight in patients with associated co-morbidities Liraglutide for obesity or overweight in patients with associated co-morbidities NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Liraglutide for obesity

2013 Health Technology Assessment (HTA) Database.

89. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials (Abstract)

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials Aside from lowering blood glucose, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) attract much attention because of their cardioprotective effects. The aim of this study was to assess the blood pressure-lowering effects of the GLP-1 RAs exenatide and liraglutide compared with other common drugs used to treat type 2 diabetes (T2DM) based on randomized controlled trials (...) (RCTs) including data describing complete blood pressure (BP) changes from baseline.We searched the major databases for published or unpublished RCTs that had been performed in patients with T2DM and compared the effects of exenatide and liraglutide to those of other common drugs used to treat T2DM. The RCTs that included data describing BP changes between the baseline and the end of the study were selected for further analysis.A total of 16 RCTs that enrolled 3443 patients in the GLP-1 RA treatment

2013 EvidenceUpdates

90. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo (Abstract)

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exenatide once weekly (ExQW) and liraglutide once daily (QD) are indicated to improve glycaemic control in patients with type 2 diabetes. Although glycaemic control with ExQW versus liraglutide QD 1.8 mg has been directly (...) compared, no studies have compared ExQW with liraglutide QD 1.2 mg or determined the probable relative efficacies of various injectable therapies for glycaemic control; therefore, a network meta-analysis was performed to address these questions.A systematic review identified randomized controlled trials of ≥24 weeks that compared ExQW, liraglutide QD (1.2 mg, 1.8 mg), insulin glargine, exenatide twice daily (ExBID), or placebo. Twenty-two studies evaluating 11 049 patients were included in the network

2013 EvidenceUpdates

91. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. (Abstract)

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Glucagon-like peptide-1 receptor agonists exenatide and liraglutide have been shown to improve glycaemic control and reduce bodyweight in patients with type 2 diabetes. We compared the efficacy and safety of exenatide once weekly with liraglutide once daily in patients with type 2 diabetes.We did a 26 week, open-label, randomised, parallel-group study at 105 sites (...) in 19 countries between Jan 11, 2010, and Jan 17, 2011. Patients aged 18 years or older with type 2 diabetes treated with lifestyle modification and oral antihyperglycaemic drugs were randomly assigned (1:1), via a computer-generated randomisation sequence with a voice response system, to receive injections of once-daily liraglutide (1·8 mg) or once-weekly exenatide (2 mg). Participants and investigators were not masked to treatment assignment. The primary endpoint was change in glycated haemoglobin

2013 Lancet Controlled trial quality: predicted high

92. Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets Full Text available with Trip Pro

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%.In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run (...) -in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks' open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change between randomized groups.Of 821 participants completing the run-in, 61% (n = 498) achieved A1C <7% (mean change -1.3% from 7.7% at start), whereas 39% (n = 323) did not (-0.6% from 8.3% at start

2012 EvidenceUpdates Controlled trial quality: uncertain

93. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

94. Liraglutide (Victoza) in type 2 diabetes. Similar to exenatide

Liraglutide (Victoza) in type 2 diabetes. Similar to exenatide 2011. DAR No 11. Liraglutide (Victoza®) in type 2 diabetes - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 11. Liraglutide (Victoza®) in type 2 diabetes DAR No 11. Liraglutide (Victoza®) in type 2 diabetes Content tools Share it Similar to exenatide The efficacy of liraglutide is similar to glimepiride and slightly higher than glargine and exenatide, although the clinical

2011 Drug and Therapeutics Bulletin of Navarre (Spain)

95. Liraglutide - Diabetes, Type 2

Liraglutide - Diabetes, Type 2 Common Drug Review CEDAC Meeting – June 15, 2011; CEDAC Reconsideration – September 21, 2011 Notice of CEDAC Final Recommendation – September 28, 2011 Page 1 of 7 © 2011 CADTH CEDAC FINAL RECOMMENDATION LIRAGLUTIDE (Victoza – Novo Nordisk Canada Inc.) Indication: Diabetes, Type 2 Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that liraglutide not be listed at the submitted price. Reasons for the Recommendation: 1. Based (...) on a systematic review including six randomized controlled trials (RCTs), liraglutide demonstrated similar or greater reductions in hemoglobin A1c in combination with metformin, or with metformin and a sulfonylurea, compared with antihyperglycemic agents from other drug classes. Liraglutide was also associated with statistically significant weight loss compared with other drug classes. The clinical significance of these results with respect to diabetes-related morbidity and mortality is unknown for this new

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

96. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents

Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

97. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

98. Victoza (Liraglutide [rDNA]) Injection

Victoza (Liraglutide [rDNA]) Injection Drug Approval Package: Victoza (Liraglutide [rDNA]) Injection Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Victoza (Liraglutide [rDNA]) Injection Company: Novo Nordisk Inc. Application No.: 022341 Approval Date: 1/25/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF

2010 FDA - Drug Approval Package

99. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

Liraglutide for the treatment of type 2 diabetes mellitus (TA203) Liraglutide for the treatment of type 2 diabetes mellitus | Guidance | NICE Liraglutide for the treatment of type 2 diabetes mellitus Technology appraisal guidance [TA203] Published date: 27 October 2010 Last updated: 01 December 2014 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2010 National Institute for Health and Clinical Excellence - Technology Appraisals

100. Liraglutide for the treatment of type 2 diabetes mellitus

Liraglutide for the treatment of type 2 diabetes mellitus Liraglutide for the treatment of type 2 diabetes mellitus Liraglutide for the treatment of type 2 diabetes mellitus National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Liraglutide for the treatment (...) of type 2 diabetes mellitus. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 203. 2010 Authors' conclusions 1.1 Liraglutide 1.2 mg daily in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is recommended as an option for the treatment of people with type 2 diabetes, only if used as described for exenatide in ‘Type 2 diabetes: the management of type 2 diabetes’ (NICE clinical guideline

2010 Health Technology Assessment (HTA) Database.